← Leaderboards
Arthur David Tinoco
University Of Puerto Rico Rio Piedras
$2,111,802
Attributed
$2,111,802
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $370.3K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,111,802 · 4
By mechanism
SC1$1,392,000 · 1
R21$370,325 · 1
S10$249,951 · 1
S15$99,526 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Puerto Rico Rio Piedras
Same institution · by research overlap
- Jose E Garcia-Arraras$16,107,544
- Wanda Rodriguez Arocho$278,884
- Sandra Pena De Ortiz$4,696,450
- John A Soderquist$661,638
- Jessica Morales-Ortiz$48,618
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignDrug DesignInsightChemistrySpecificityOverexpressionNormal CellPharmaceutical PreparationsLigandsIonsAntineoplastic AgentsMalignant NeoplasmsAffinityInnovationDrug TargetingCellsCancer CellBiological AvailabilityBiologyCytotoxicBaseCell DeathGenerationsMetals
Grant awards (7)
Enhancing Biomedical Infrastructure and researcher Capacity through the Acquisition of Class II, Type A2 Biosafety Cabinets$99,526
S15 · FY2025 · OD · contact PI
Enhancing Biomedical Education and Research through the Acquisition of an Electron Paramagnetic Resonance Instrument$249,951
S10 · FY2024 · GM · contact PI
Fusing the commercial drugs triapine and deferasirox to create Ti(IV) anticancer compounds that inhibit the bioavailability of iron$370,325
R21 · FY2020 · CA · contact PI
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer D$348,000
SC1 · FY2017 · CA · contact PI
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer D$348,000
SC1 · FY2016 · CA · contact PI
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer D$348,000
SC1 · FY2015 · CA · contact PI
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer D$348,000
SC1 · FY2014 · CA · contact PI